What happens when a life-saving medication meets the complexities of pregnancy? The question “Is naloxone safe in pregnancy?” isn’t just medical—it’s deeply personal for many expecting mothers and healthcare providers. In this article, we uncover the facts, address the uncertainties, and explore what current evidence really says—because the answer may not be as straightforward as you think.
Get expert guidance on naloxone use in pregnancy—Schedule your consultation today!
TL;DR:
Naloxone is generally considered safe to use during pregnancy in emergency overdose situations. While it may trigger opioid withdrawal in both mother and fetus—leading to potential risks like preterm labor or fetal distress—it has not been linked to birth defects. Clinical guidelines support its use, emphasizing maternal survival. After administration, careful monitoring and follow-up care for both mother and newborn are essential to manage withdrawal effects and support recovery.
What Risks Are Involved with Naloxone Use During Pregnancy?
Naloxone use during pregnancy carries certain risks, primarily related to how it interacts with opioid dependence rather than from the drug itself. According to FDA classifications, administered via intramuscular or subcutaneous routes falls under category B—indicating that animal studies have not shown harm to the fetus. Nonetheless, in some cases, it is listed as category C due to limited human data and the fact that it crosses the placenta.
The most significant risk arises when naloxone is administered to a pregnant individual who is opioid-dependent. In such cases, it can precipitate sudden opioid withdrawal in both the mother and fetus. For the fetus, this may lead to distress or trigger preterm labor. For the mother, withdrawal symptoms such as nausea, agitation, and rapid heart rate (tachycardia) may occur. These maternal symptoms can potentially affect uterine blood flow and reduce oxygen delivery to the fetus.
Another concern is maternal hypertension during labor. If it is given to someone with pre-existing high blood pressure, it may cause a spike in blood pressure, posing additional risks during delivery. Despite these potential complications, it is important to note that this medication has not been shown to cause birth defects or long-term harm to the fetus when used appropriately in emergency situations.
Naloxone Safety in Pregnancy
This medication has been used in a limited number of pregnant individuals without reports of teratogenic (birth-defect) effects in either animal or human studies. Much of the available data comes from its use in combination with buprenorphine for treating opioid use disorder. In these cases, naloxone—often part of a buprenorphine-naloxone formulation—has not been associated with an increased risk of congenital anomalies or adverse birth outcomes when compared to buprenorphine alone or methadone.
Some studies even suggest potential benefits when using buprenorphine-naloxone during pregnancy. These include lower rates of neonatal abstinence syndrome (NAS), fewer admissions to neonatal intensive care units (NICUs), and smaller-than-expected birth size compared to outcomes observed with buprenorphine alone.
Clinical guidelines from organizations such as the CDC and ACOG underscore that it should not be withheld during pregnancy if it is needed to reverse an opioid overdose. Maternal survival is the immediate priority, and any risks related to withdrawal can be managed under medical supervision.
Risks of Opioid Overdose During Pregnancy
Opioid overdose during pregnancy is a critical concern with potentially life-threatening consequences for both mother and fetus. It is not only a medical emergency but also a leading contributor to maternal mortality in some regions. Comprehending these risks highlights the importance of timely intervention and access to overdose-reversal medications.
- Leading Cause of Maternal Death: In several areas, opioid overdose surpasses other obstetric causes as a top contributor to pregnancy-associated mortality.
- Maternal and Fetal Harm: Overdose can result in hypoxia, respiratory arrest, or death in the mother, increasing the likelihood of fetal stillbirth, distress, or preterm labor.
- Ongoing Opioid Use Risks: Continued opioid use during pregnancy is associated with lower birth weight, intrauterine growth restriction, pre-eclampsia, and neonatal abstinence syndrome (NAS).
- Public Health Priority: Expanding access to naloxone for pregnant and postpartum individuals with opioid use disorder is an evidence-based strategy to reduce maternal deaths and protect infant health.
When to Use Naloxone
Naloxone should be used during pregnancy only in clear cases of suspected opioid overdose. Prompt action is critical, as the health and survival of the mother directly impact fetal outcomes. Recognizing the signs and responding quickly can be life-saving.
Should be administered when the following signs are present:
- Unresponsiveness
- Very slow or absent breathing
- Pinpoint pupils
These symptoms may result from an overdose involving illicit opioids, prescription misuse, or dangerous interactions with substances like benzodiazepines or alcohol.
Leading healthcare authorities recommend the following:
- Do not delay its administration in pregnant individuals during an overdose. The immediate priority is to save the mother’s life, even though withdrawal risks exist.
- Keep naloxone kits accessible for pregnant individuals with opioid use disorder, and ensure that family members or caregivers are trained to administer it.
- Use the lowest effective dose, repeating as needed until normal breathing resumes. Small, staged doses may help reduce the severity of sudden opioid withdrawal.
Timely use of naloxone can prevent fatal outcomes and support safer recovery for both mother and baby.
Medical Guidance After Naloxone Use
After naloxone is administered during pregnancy, continuous medical monitoring is essential for both the mother and fetus. Fetal heart rate and uterine activity should be closely observed to detect any signs of distress or preterm labor, particularly if opioid withdrawal has been triggered. At the same time, the mother must be monitored for rebound opioid toxicity—if naloxone wears off before the effects of longer-acting opioids subside—as well as for cardiovascular instability and severe withdrawal symptoms.
Ongoing obstetric and pediatric care should be maintained. If the mother has an opioid use disorder, treatment options such as methadone or buprenorphine should be coordinated promptly. Newborns exposed to opioids in utero must be evaluated for neonatal abstinence syndrome (NAS), which may require hospitalization and either supportive or pharmacologic treatment.
Long-term planning should also include discussions about substance use treatment and postpartum support, as the risk of overdose continues after delivery. Sustained treatment engagement is essential to improving outcomes for both mother and baby.
Key Takeaways
- Primary Concern: The central question—is naloxone safe in pregnancy—requires balancing maternal survival with potential fetal risks. Current evidence emphasizes safety when used appropriately.
- Risks of Use: It may trigger sudden opioid withdrawal in both the mother and fetus, potentially leading to fetal distress, preterm labor, or maternal symptoms like nausea and tachycardia. It may also raise blood pressure in labor, but it has not been linked to birth defects or long-term harm.
- Safety Evidence: Naloxone has not shown teratogenic effects in animal or human studies. When used as part of buprenorphine-naloxone treatment, it has not increased birth risks and may reduce rates of neonatal abstinence syndrome (NAS) and NICU admission.
- Overdose Dangers: Opioid overdose during pregnancy is a leading cause of maternal death in many areas and can cause severe harm to the fetus. Risks include stillbirth, low birth weight, preterm labor, and NAS.
- When to Administer Naloxone: It should be used immediately in pregnant individuals showing signs of opioid overdose (e.g., unresponsiveness, slow breathing, pinpoint pupils). The mother’s survival is the top priority, and timely use can prevent fatal outcomes.
- Dosage and Access: Naloxone should be administered in the lowest effective dose and repeated as needed. Family or caregivers should be trained, and kits should be easily accessible for individuals at risk.
- Post-Use Medical Guidance: After naloxone use, both maternal and fetal monitoring is essential. This includes checking for withdrawal effects, cardiovascular changes, and signs of preterm labor or fetal distress.
- Continued Care: Mothers with opioid use disorder should receive coordinated treatment (e.g., methadone or buprenorphine). Infants should be screened for NAS, and postpartum care should include long-term substance use treatment planning to prevent relapse and improve outcomes.
Sources.
Ordean, A., & Tubman-Broeren, M. (2023). Safety and efficacy of buprenorphine-naloxone in pregnancy: a systematic review of the literature. Pathophysiology, 30(1), 27-36. Doi: https://doi.org/10.3390/pathophysiology30010004
Board, A., D’Angelo, D. V., Miele, K., Asher, A., von Essen, B. S., Denny, C. H., … & Kim, S. Y. (2024). Naloxone Use During Pregnancy—Data From 26 US Jurisdictions, 2019–2020. Journal of addiction medicine, 18(6), 711-714. Retrieved from: https://journals.lww.com/journaladdictionmedicine/abstract/2024/11000/naloxone_use_during_pregnancy_data_from_26_us.17.aspx